Combination therapeutics for the world's toughest diseases
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
Total raised
$9M
Last stage
Seed
Investors
Tom Roseberry
Tom has over 15 years of industry experience leading teams and engineering technologies in aerospace, brain machine interfacing, synthetic biology and drug discovery/development. At Neuralink he built and co-led a group that developed a next-generation neural interface. At Loyal he built and led multiple teams as VP of Engineering, Computational Biology and Drug Development.
LinkedInDavid Tingley
PhD in Neuroscience from New York University; postdoctoral research at Harvard. Over 13 years of experience as a systems neuroscientist and biologist. Published 15+ scientific articles including a Nature 2020 paper on brain activity and glucose metabolism.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.